Link Cell Therapies Analysis: $88M Raised
What is Link Cell Therapies?
Link Cell Therapies develops CAR T cell therapies targeting solid tumors using proprietary AND-gate technology. This technology requires co-expression of cancer targets, enhancing specificity and safety in treatment. The company aims to advance multiple therapeutic programs for various cancer indications.
Funding Status
Series A
Product Features & Capabilities
- AND-gate CAR T cell therapies
- Preclinical development of CAR T and CAR NK cell therapies
- Research and development in cell therapy
- Protein sciences for antibody discovery
Use Cases
Targeting solid tumors with enhanced specificity; Developing CAR T therapies for pediatric cancers; Advancing preclinical studies for hematologic cancers; Engineering CAR T cells to overcome therapeutic resistance; Collaborating on antibody drug conjugate development
Other Considerations
Founders are Stanford researchers with significant expertise; Recent publication in Nature on CAR T technology; Backed by Samsara BioCapital; Leadership team with extensive industry experience
See something that needs updating? Suggest edits to this profile.